Amalgamated Bank’s Accelerate Diagnostics AXDX Stock Holding History

Amalgamated Bank’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-537	Closed	-$8K	–	3043
2022 Q1	$8K	Buy	+537	New	+$15.3K	﹤0.01%	2985

Other funds holding AXDX

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Amalgamated Bank's AXDX Position: Q2 2022 in Review

Amalgamated Bank sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 537 shares — an estimated $8K sold.

Amalgamated Bank first reported a position in AXDX in Q1 2022 and held it in 1 quarter. The position peaked at $8K in Q1 2022. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

Amalgamated Bank reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
Amalgamated Bank sold 537 Accelerate Diagnostics shares in Q2 2022, an estimated $8K.
Amalgamated Bank first reported a position in Accelerate Diagnostics in Q1 2022 and held it in 1 quarter.
Amalgamated Bank's Accelerate Diagnostics position peaked at $8K in Q1 2022.
74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.